17-allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1

Sato, Akinori; Ito, Keiichi; Asano, Tomohiko

doi:10.3892/ijo.2012.1419

Cited by 16 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We demonstrated an additive effect on cell death in PANC-1 cells, suggesting the benefits of ritonavir as part of combination therapy. Of note, there is a beneficial effect of combining 7-allylamino-17-demethoxygeldanamycin and ritonavir as a novel therapeutic target by inhibiting the expression of heat shock factor-1 in the treatment of renal cancer [18]. …”

Section: Discussionmentioning

confidence: 99%

Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways

et al. 2014

View full text Add to dashboard Cite

Recent observations suggest a lower incidence of malignancies in patients infected with HIV during treatment with Highly Active Anti-Retroviral Therapy (HAART) utilizing protease inhibitors. We investigated the effects of ritonavir, a FDA approved HIV protease inhibitor, on proliferation of pancreatic ductal adeno-carcinoma (PDAC) cell lines. Human PDAC cell lines BxPC-3, MIA PaCa-2, and PANC-1 were propagated under standard conditions and treated with serial dilutions of ritonavir. Ritonavir inhibited cell growth in a dose-dependent manner as well as activated the intrinsic apoptotic pathway in human pancreatic ductal adenocarcinoma (PDAC) cell lines. We observed down-modulation of cell-cycle promoting and up-regulation of cell-cycle inhibitory genes; enhanced interaction of retinoblastoma protein (RB) with E2F-1 transcription factor; inhibition of phosphorylation of RB, resulting in sequestration of E2F-1 and subsequent down-regulation of S phase genes; decreased interaction of E2F-1 with its consensus binding sites; inhibition of cell motility and invasiveness; and inhibition of the AKT pathway. Our results demonstrate a potential use of ritonavir as part of combination chemotherapy for PDAC. Since ritonavir is FDA approved for HIV, drug repositioning for PDAC would limit the costs and reduce risks.

show abstract

Section: Discussionmentioning

confidence: 99%

Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In the present study, ritonavir itself exhibited antiproliferative activity against renal cancer cells, suggesting that it may not only act as a CYP3A4 inhibitor. Ritonavir was recently shown to exert antitumor effects through the inhibition of proteins such as nuclear factor-κB (14) and heat shock protein (HSP) 90 (15) and it was also reported to inhibit renal cancer growth by inhibiting heat shock factor 1, a transcription factor of HSP 90, when used in combination with 17-allylamino-17-demethoxygeldanamycin (16). Furthermore, the inhibition of HDACs, particularly HDAC6, acetylates HSP 90 and suppresses its function as a molecular chaperone (17).…”

Section: Discussionmentioning

confidence: 99%

Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth

Sato

Isono

Ito

et al. 2014

Molecular and Clinical Oncology

Self Cite

View full text Add to dashboard Cite

Abstract. There is currently no curative treatment for advanced renal cancer. Enhancing histone acetylation is a promising epigenetic-based therapy for cancer; however, in solid tumors, the efficacy of histone deacetylase (HDAC) inhibitors alone is limited. The human immunodeficiency virus protease inhibitor ritonavir is also a CYP3A4 inhibitor and we hypothesized that combining ritonavir with the HDAC inhibitor panobinostat, one of the substrates of CYP3A4, may effectively eliminate renal cancer cells by enhancing the activity of panobinostat. The combination of ritonavir and panobinostat synergistically inhibited cancer cell growth and cancer cell colony formation, while only slightly inhibiting the growth of renal proximal tubule epithelial cells. This combination significantly induced apoptosis in cancer cells and this apoptosis was considered to be caspase-dependent, since the pan-caspase inhibitor Z-VAD-FMK reduced the number of Annexin V-positive cells. In murine subcutaneous xenograft models using Caki-1 cells, a 10-day treatment with the combination of ritonavir and panobinostat significantly inhibited tumor growth. Panobinostat alone increased histone acetylation in a dose-dependent manner and the co-administration of ritonavir synergistically enhanced this acetylation. Furthermore, this combination inhibited the expression of HDACs, which may also play a role in the enhancement of histone acetylation. Thus, the present study may provide a basis for testing the combination of ritonavir and panobinostat for patients with advanced renal cancer.

show abstract

“…Small molecule inhibitors of the chaperone HSP90 are a growing class of clinically utilized anti-tumorigenic agents that have been collectively employed as an alternative means of targeting HIF-1α (21). This focus on these inhibitors is due to their shared ability to disrupt the ATP-dependent chaperone activity of HSP90 and block the protein folding of HSP90 client proteins (21).…”

Section: Discussionmentioning

confidence: 99%

“…This focus on these inhibitors is due to their shared ability to disrupt the ATP-dependent chaperone activity of HSP90 and block the protein folding of HSP90 client proteins (21). Previous studies have revealed that the HSP90 inhibitors geldanamycin, 17-AAG and 17-dimethylaminoethylamino-17-demethoxygeldanamycin demonstrate anti-tumorigenic and anti-angiogenic properties in vitro and in vivo in animal models, which is partly due to the ability of these agents to inhibit the function of HIF (22,23).…”

Section: Discussionmentioning

confidence: 99%

Effects of the novel heat shock protein 90 inhibitor AUY922 in renal cell carcinoma ACHN and 786-O cells

Zhu

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the effects of the heat shock protein (HSP)90 inhibitor AUY922 on the proliferation and migratory ability of renal cell carcinoma (RCC) cells. The expression of HSP90 was measured in vitro using western blotting and quantitative polymerase chain reaction in the ACHN and 786-O cell RCC lines, and also in the immortalized normal human proximal tubule epithelium HK-2 cell line. The effects of the time and concentration of AUY922 administration were investigated in the ACHN and 786-O cells, and the cell proliferation was measured using an MTT assay. A Transwell assay was performed to evaluate the migratory ability of ACHN cells following treatment with AUY922 at concentrations of 10, 50 and 100 nM. Western blot analysis and reverse transcription polymerase chain reaction revealed that HSP90 mRNA and protein were overexpressed in the two RCC cell lines compared with the HK-2 cell line. AUY922 inhibited the proliferation of the ACHN and 786-O cells in a time-and concentration-dependent manner, and the migratory ability of the ACHN cells was markedly suppressed subsequent to treatment with AUY922. The present data suggest that the pathogenesis of human RCC may be mediated by HSP90. It was also indicated that the specific HSP90 inhibitor AUY922 plays a therapeutic role in the treatment of RCC, and therefore, HSP90 may be a selective target for molecular-targeted treatments of RCC.

show abstract

17-allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1

Cited by 16 publications

References 24 publications

Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways

Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways

Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth

Effects of the novel heat shock protein 90 inhibitor AUY922 in renal cell carcinoma ACHN and 786-O cells

Contact Info

Product

Resources

About